HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

This article was originally published in The Rose Sheet

Executive Summary

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

You may also be interested in...



US Cosmetics Reform Talks To Resume In 2021 After COVID Derailing, Anti-Regulation Trump

Efforts to modernize US cosmetics regulations fell short in the 116th Congress as lawmakers swung their focus to COVID-19, but industry expects a resumption of discussions in the next term, even as pandemic relief and recovery remains top priority.

FDA Rulemaking Could Be Imminent On Investigational New Drug Requirements For Cosmetics, Dietary Supplements

Are investigational new drug applications required for clinical trials conducted by cosmetics companies to evaluate potential body structure/function effects, or clinical studies undertaken by dietary supplement companies to support a new or expanded health claim? FDA said they are in final guidance reissued in late 2015 and now has rulemaking planned on the subject that could commence this month.

2017 In Review: FDA's Cosmetics Slowdown Could Bolster Case For Legislative Jumpstart

FDA's cosmetics activities fell off noticeably compared with 2016, and the change in the White House spurred the agency to begin looking for regulatory burdens to eliminate while shuffling priorities away from cosmetics to make do with proposed cuts in federal funding. In this climate, robust cosmetics oversight may depend on a legislative update, with multiple draft bills on the table.

Related Content

Topics

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel